OKUR OnKure Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OKUR matters now
OnKure Therapeutics, Inc. (OKUR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.28 with -4.04% on the session and $58.5M in market capitalization; recent performance reads 1-month +35.76% and YTD +54.48%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-15.2M, and EPS of $-1.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -82.9%.
The latest indexable market news headline is "OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes Carruthers R Michael filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.33
P/S
0.00
EV/EBITDA
2.25
DCF Value
$4.23
FCF Yield
-82.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.0%
ROA
-29.6%
ROIC
-33.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-15.2M | $-1.11 |
| Q4 2025 | $0.00 | $-13.5M | $-0.99 |
| FY 2025 | $0.00 | $-59.5M | $-4.40 |
| Q3 2025 | $0.00 | $-14.7M | $-1.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.00
Target (Median)
$35.00
Target Range
$35.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.